Given the clinical efficacy of the Atezolizumab plus Bevacizumab combination and the prominent role of angiogenesis in HCC biology, the exploration of VEGF inhibition to normalize the tumor vasculature may be also warranted for HCC in situ vaccination concepts (12, 230). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.